NewAmsterdam Pharma Co. N.V. (NAMS) on GreekSoup https://greeksoup.ai/stocks/us/nams/ Every dated entry in the public record on NewAmsterdam Pharma Co. N.V.: results, filings, insider trades and the rest, from the filings, the last 90 days. en Wed, 28 Oct 2026 00:00:00 +0000 NewAmsterdam Pharma Co. N.V.: short interest 14,110,048 shares at the 15 October 2026 settlement, 10.64 days to coverhttps://greeksoup.ai/stocks/us/nams/short-interest/us:NAMS:short-interest:2026-10-15:f02095ebb4Thu, 15 Oct 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> NewAmsterdam Pharma Co. N.V.: Kastelein Johannes Jacob Pieter (Chief Scientific Officer), see footnotes, sold 50,246 shares (under a trading plan set in advance) at $25.03 on 30 September 2026, $1.3 millionhttps://greeksoup.ai/stocks/us/nams/insiders/us:NAMS:insider:2026-10-02:2374818720Fri, 02 Oct 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> NewAmsterdam Pharma Co. N.V.: short interest 19,045,378 shares at the 30 September 2026 settlement, 9.39 days to coverhttps://greeksoup.ai/stocks/us/nams/short-interest/us:NAMS:short-interest:2026-09-30:4d89f73726Wed, 30 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> NewAmsterdam Pharma Co. N.V. filed 8-K: other eventshttps://greeksoup.ai/stocks/us/nams/filings/us:NAMS:filing:2026-09-29:6c4acd4533Tue, 29 Sep 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> NewAmsterdam Pharma Co. N.V.: Schedule 13D/A filed by Frazier Life Sciences X, L.P., 8.7% of the classhttps://greeksoup.ai/stocks/us/nams/holders/us:NAMS:schedule-13:2026-09-22:6e70fff2d2Tue, 22 Sep 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> NewAmsterdam Pharma Co. N.V. filed 8-K: other eventshttps://greeksoup.ai/stocks/us/nams/filings/us:NAMS:filing:2026-09-21:beb6d5299fMon, 21 Sep 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> NewAmsterdam Pharma Co. N.V.: Davidson Michael H. (Chief Executive Officer) bought 10,000 shares at $22.65 on 14 September 2026, $226,500https://greeksoup.ai/stocks/us/nams/insiders/us:NAMS:insider:2026-09-15:8aefc52d3cTue, 15 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> NewAmsterdam Pharma Co. N.V.: short interest 15,660,444 shares at the 15 September 2026 settlement, 9.88 days to coverhttps://greeksoup.ai/stocks/us/nams/short-interest/us:NAMS:short-interest:2026-09-15:a3a38d8e2eTue, 15 Sep 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> NewAmsterdam Pharma Co. N.V.: Smither John W (Director) sold 1,600 shares at $25.32 on 4 September 2026, $40,512https://greeksoup.ai/stocks/us/nams/insiders/us:NAMS:insider:2026-09-09:803c85fc35Wed, 09 Sep 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> NewAmsterdam Pharma Co. N.V.: short interest 13,392,021 shares at the 31 August 2026 settlement, 13.36 days to coverhttps://greeksoup.ai/stocks/us/nams/short-interest/us:NAMS:short-interest:2026-08-31:d3c6804590Mon, 31 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> NewAmsterdam Pharma Co. N.V.: Kastelein Johannes Jacob Pieter (Chief Scientific Officer), see footnotes, sold 125,000 shares (under a trading plan set in advance) at $26.91 on 24 August 2026, $3.4 millionhttps://greeksoup.ai/stocks/us/nams/insiders/us:NAMS:insider:2026-08-25:0a94907075Tue, 25 Aug 2026 00:00:00 +0000Insider tradeInsider trade. The filing. The page on GreekSoup.

]]> NewAmsterdam Pharma Co. N.V.: Form 144, Kastelein Johannes Jacob Pieter plans to sell 125,000 shares worth $3.5 million around 24 August 2026https://greeksoup.ai/stocks/us/nams/planned-sales/us:NAMS:planned-sale:2026-08-24:80cd3729b0Mon, 24 Aug 2026 00:00:00 +0000Form 144Form 144. The filing. The page on GreekSoup.

]]> NewAmsterdam Pharma Co. N.V. filed 8-K/A: officer or director changehttps://greeksoup.ai/stocks/us/nams/filings/us:NAMS:filing:2026-08-14:641e301512Fri, 14 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> NewAmsterdam Pharma Co. N.V. filed 8-K: officer or director changehttps://greeksoup.ai/stocks/us/nams/filings/us:NAMS:filing:2026-08-14:d6158b9e04Fri, 14 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> NewAmsterdam Pharma Co. N.V.: short interest 12,654,106 shares at the 14 August 2026 settlement, 9.92 days to coverhttps://greeksoup.ai/stocks/us/nams/short-interest/us:NAMS:short-interest:2026-08-14:285a14ab51Fri, 14 Aug 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]> NewAmsterdam Pharma Co. N.V.: Schedule 13G/A filed by FMR LLC, 8.8% of the classhttps://greeksoup.ai/stocks/us/nams/holders/us:NAMS:schedule-13:2026-08-06:c88c5bf1d1Thu, 06 Aug 2026 00:00:00 +0000Schedule 13D/13GSchedule 13D/13G. The filing. The page on GreekSoup.

]]> NewAmsterdam Pharma Co. N.V. Q2 FY2026 results: revenue $4 million, net income -$64 millionhttps://greeksoup.ai/stocks/us/nams/results/fy2026-q2/us:NAMS:result:2026-08-05:fbd92ef03dWed, 05 Aug 2026 00:00:00 +0000ResultsResults. The filing. The page on GreekSoup.

]]> NewAmsterdam Pharma Co. N.V. filed 8-K: results of operationshttps://greeksoup.ai/stocks/us/nams/filings/us:NAMS:filing:2026-08-05:970fb9a5cdWed, 05 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> NewAmsterdam Pharma Co. N.V. filed 10-Q: 10-qhttps://greeksoup.ai/stocks/us/nams/filings/us:NAMS:filing:2026-08-05:471240b0a2Wed, 05 Aug 2026 00:00:00 +0000SEC filingSEC filing. The filing. The page on GreekSoup.

]]> NewAmsterdam Pharma Co. N.V.: short interest 9,959,761 shares at the 31 July 2026 settlement, 9.77 days to coverhttps://greeksoup.ai/stocks/us/nams/short-interest/us:NAMS:short-interest:2026-07-31:6328b82cdaFri, 31 Jul 2026 00:00:00 +0000Short interestShort interest. The filing. The page on GreekSoup.

]]>